DKK1,437.50
1.78% yesterday
Copenhagen, Jul 31, 05:00 pm CET
ISIN
DK0010272202
Symbol
GMAB

Genmab A/S Stock price

DKK1,437.50
+122.50 9.32% 1M
+13.00 0.91% 6M
-55.00 3.69% YTD
-517.50 26.47% 1Y
-1,154.50 44.54% 3Y
-721.50 33.42% 5Y
+798.00 124.79% 10Y
+1,333.00 1,275.60% 20Y
Copenhagen, Closing price Thu, Jul 31 2025
-26.00 1.78%
ISIN
DK0010272202
Symbol
GMAB
Industry

Key metrics

Basic
Market capitalization
DKK90.2b
Enterprise Value
DKK87.1b
Net debt
positive
Cash
DKK3.2b
Shares outstanding
63.3m
Valuation (TTM | estimate)
P/E
39.3 | 13.8
P/S
11.4 | 24.8
EV/Sales
11.0 | 24.0
EV/FCF
negative
P/B
17.0
Financial Health
Equity Ratio
80.1%
Return on Equity
21.4%
ROCE
42.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
DKK7.9b | DKK3.6b
EBITDA
DKK2.6b | DKK8.7b
EBIT
DKK2.5b | DKK7.8b
Net Income
DKK2.4b | DKK6.7b
Free Cash Flow
DKK-90.4m
Growth (TTM | estimate)
Revenue
-55.3% | 10.8%
EBITDA
- | 693.0%
EBIT
-56.4% | 626.5%
Net Income
-56.3% | 462.6%
Free Cash Flow
-101.7%
Margin (TTM | estimate)
Gross
95.9%
EBITDA
32.2% | 239.1%
EBIT
31.2%
Net
30.0% | 185.0%
Free Cash Flow
-1.1%
More
EPS
DKK37.3
FCF per Share
DKK-1.4
Short interest
-
Employees
3k
Rev per Employee
DKK1.2m
Show more

Is Genmab A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,020 stocks worldwide.

Genmab A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Genmab A/S forecast:

21x Buy
72%
7x Hold
24%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Genmab A/S forecast:

Buy
72%
Hold
24%
Sell
3%

Financial data from Genmab A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7,942 7,942
55% 55%
100%
- Direct Costs 325 325
21% 21%
4%
7,617 7,617
42% 42%
96%
- Selling and Administrative Expenses 1,342 1,342
61% 61%
17%
- Research and Development Expense 3,615 3,615
56% 56%
46%
2,556 2,556
-
32%
- Depreciation and Amortization 79 79
-
1%
EBIT (Operating Income) EBIT 2,477 2,477
56% 56%
31%
Net Profit 2,382 2,382
56% 56%
30%

In millions DKK.

Don't miss a Thing! We will send you all news about Genmab A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today